REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) will participate in several upcoming virtual investor conferences in March 2021. The events include:

• Raymond James 42nd Annual Institutional Investors Conference: March 3, 2021, at 10:50 a.m. ET
• Barclays Global Healthcare Conference: March 9, 2021, at 4:10 p.m. ET
• Morgan Stanley Virtual Healthcare Corporate Access Day: March 16, 2021

Live webcasts for the Raymond James and Barclays events will be available on REGENXBIO's website, with archived versions accessible for 30 days post-event.

ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtual meeting format:

Raymond James 42^nd Annual Institutional Investors Conference
Fireside chat: Wednesday, March 3, 2021 at 10:50 a.m. ET

Barclays Global Healthcare Conference
Fireside chat: Tuesday, March 9, 2021 at 4:10 p.m. ET

Morgan Stanley Virtual Healthcare Corporate Access Day
Date: Tuesday, March 16, 2021

Live webcasts of the Raymond James and Barclays fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available on the same website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV^® Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301234852.html

SOURCE REGENXBIO Inc.

FAQ

What investor conferences will REGENXBIO participate in March 2021?

REGENXBIO will participate in the Raymond James 42nd Annual Institutional Investors Conference on March 3, Barclays Global Healthcare Conference on March 9, and Morgan Stanley Virtual Healthcare Corporate Access Day on March 16, 2021.

What are the details for the Raymond James conference participation by RGNX?

REGENXBIO's fireside chat at the Raymond James conference is scheduled for March 3, 2021, at 10:50 a.m. ET.

How can I access the webcasts for REGENXBIO's investor conferences?

Live webcasts for the Raymond James and Barclays conferences can be accessed on REGENXBIO's website, with archived replays available for approximately 30 days after each event.

What is the focus of REGENXBIO as a biotechnology company?

REGENXBIO focuses on gene therapy and utilizes its NAV Technology Platform for developing candidates in various therapeutic areas.